Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 3/20 | 0.34 |
| ▸ | PLK1 | P53350 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212372 | 0.86 | NEK2 (0.35) | NEK2PLK1LRRK2RPS6KA5YTHDC1 | |
| SCHEMBL10212386 | 0.84 | LRRK2 (0.34) | NEK2PLK1LRRK2DYRK1AGSK3B | |
| SCHEMBL11938830 | 0.83 | NEK2 (0.39) | NEK2PLK1LRRK2RPS6KA5 | |
| SCHEMBL182323 | 0.78 | NEK2 (0.50) | NEK2PLK1RPS6KA5 | |
| SCHEMBL182322 | 0.78 | NEK2 (0.50) | NEK2PLK1RPS6KA5 | |
| SCHEMBL10212389 | 0.74 | NEK2 (0.52) | NEK2DYRK1AJAK2 | |
| SCHEMBL16125483 | 0.69 | KIF11 (0.45) | DYRK1AGSK3BPDPK1JAK2 | |
| Nitrous Acid SCHEMBL11021890 | 0.67 | NEK2 (0.35) | NEK2PLK1LRRK2DYRK1ARPS6KA5 | |
| Nitrous Acid SCHEMBL11021891 | 0.67 | NEK2 (0.35) | NEK2PLK1LRRK2DYRK1ARPS6KA5 | |
| SCHEMBL10212410 | 0.67 | ADORA2A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | NEK2 827/4885PLK1 1039/4885LRRK2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.